Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Precision dosing could transform sickle cell care in nigeria

NCT ID NCT07543289

First seen Apr 21, 2026 · Last updated May 25, 2026 · Updated 10 times

Summary

This study aims to make hydroxyurea therapy safer and more effective for 100 Nigerian patients with sickle cell disease. Researchers will analyze genetics, drug levels, and patient responses to create a personalized dosing guide. The goal is to reduce painful crises and improve quality of life by tailoring treatment to each individual.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Obafemi Awolowo University Teaching Hospital Complex

    Ile-Ife, Osun State, 220282, Nigeria

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.